Savara (SVRA) Income towards Parent Company (2010 - 2026)
Savara (SVRA) reported Income towards Parent Company of -$37.9 million for Q1 2026, down 42.4% year-over-year from -$65.9 million in Q1 2025, and down 17.72% on a QoQ basis from -$32.2 million in Q4 2025.
Savara (SVRA) has 17 years of Income towards Parent Company data on file, last reported at -$37.9 million in Q1 2026.
- Quarterly Income towards Parent Company fell 42.4% year-over-year to -$37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.4 million (down 27.52% YoY) and the FY2025 annual result came in at -$119.4 million, down 23.42% from the prior year.
- Income towards Parent Company fell to -$37.9 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$8.6 million in Q1 2022 and bottomed at -$37.9 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$20.3 million (2024), against an average of -$20.4 million.
- The widest annual swing landed in 2022, when Income towards Parent Company gained 21.72%; it then tumbled 92.13% in 2024.
- Tracing SVRA's Income towards Parent Company over 5 years: stood at -$10.3 million in 2022, then slumped by 57.01% to -$16.1 million in 2023, then tumbled by 81.62% to -$29.3 million in 2024, then slipped by 10.13% to -$32.2 million in 2025, then declined by 17.72% to -$37.9 million in 2026.
- Per Business Quant, the three latest SVRA Income towards Parent Company figures stand at -$37.9 million (Q1 2026), -$32.2 million (Q4 2025), and -$29.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.93 Mn |
| Dec 31, 2025 | -32.22 Mn |
| Sep 30, 2025 | -29.71 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.26 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | -22.12 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.11 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.51 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.26 Mn |
| Sep 30, 2022 | -10.38 Mn |
| Jun 30, 2022 | -9.67 Mn |
| Mar 31, 2022 | -8.62 Mn |
| Dec 31, 2021 | -11.20 Mn |
| Sep 30, 2021 | -10.54 Mn |
| Jun 30, 2021 | -11.01 Mn |
| Mar 31, 2021 | -11.01 Mn |
| Dec 31, 2020 | -13.54 Mn |
| Sep 30, 2020 | -11.24 Mn |
| Jun 30, 2020 | -9.39 Mn |
| Mar 31, 2020 | -15.42 Mn |
| Dec 31, 2019 | -31.72 Mn |
| Sep 30, 2019 | -12.40 Mn |
| Jun 30, 2019 | -21.94 Mn |
| Mar 31, 2019 | -12.11 Mn |
| Dec 31, 2018 | -15.52 Mn |
| Sep 30, 2018 | -12.45 Mn |
| Jun 30, 2018 | -11.32 Mn |
| Mar 31, 2018 | -26.85 Mn |
| Dec 31, 2017 | -1.61 Mn |
| Sep 30, 2017 | -6.82 Mn |
| Jun 30, 2017 | -11.50 Mn |
| Mar 31, 2017 | -4.97 Mn |
| Dec 31, 2016 | -2.80 Mn |
| Sep 30, 2016 | -3.23 Mn |
| Jun 30, 2016 | -2.05 Mn |
| Mar 31, 2016 | -2.17 Mn |
| Dec 31, 2015 | -12.16 Mn |
| Sep 30, 2015 | -9.90 Mn |
| Jun 30, 2015 | -10.15 Mn |
| Mar 31, 2015 | -9.62 Mn |
| Dec 31, 2014 | -7.34 Mn |
| Sep 30, 2014 | -7.87 Mn |
| Jun 30, 2014 | -7.19 Mn |
| Mar 31, 2014 | -6.82 Mn |
| Dec 31, 2013 | -5.70 Mn |
| Sep 30, 2013 | -5.25 Mn |
| Jun 30, 2013 | -4.94 Mn |
| Mar 31, 2013 | -5.58 Mn |
| Dec 31, 2012 | -4.00 Mn |
| Sep 30, 2012 | -3.20 Mn |
| Jun 30, 2012 | -4.20 Mn |
| Mar 31, 2012 | -4.16 Mn |
| Dec 31, 2011 | -2.44 Mn |
| Sep 30, 2011 | -3.55 Mn |
| Jun 30, 2011 | -4.40 Mn |
| Mar 31, 2011 | -2.96 Mn |
| Dec 31, 2010 | -2.28 Mn |
| Sep 30, 2010 | -1.84 Mn |
| Jun 30, 2010 | -1.92 Mn |